Recent Progress in the Pharmacotherapy of Alzheimer’s Disease
| Autor: | Jake Gold, Kush Patel, Stephanie Hinds, George T. Grossberg, Rita Khoury |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Drug medicine.medical_specialty media_common.quotation_subject Tau protein Disease medicine.disease_cause Bioinformatics Receptors N-Methyl-D-Aspartate 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Alzheimer Disease Memantine medicine Humans Pharmacology (medical) Molecular Targeted Therapy Psychiatry media_common Amyloid beta-Peptides biology business.industry Oxidative Stress 030104 developmental biology biology.protein Biomarker (medicine) Cholinesterase Inhibitors Geriatrics and Gerontology business Excitatory Amino Acid Antagonists Neurocognitive Biomarkers 030217 neurology & neurosurgery Oxidative stress medicine.drug |
| Zdroj: | Drugs & Aging. 34:811-820 |
| ISSN: | 1179-1969 1170-229X |
| DOI: | 10.1007/s40266-017-0499-x |
| Popis: | Alzheimer's disease is the most common major neurocognitive disorder with substantial social and economic impacts. This article is an update on current pharmacotherapy, advancements in biomarker use, and drugs in the pipeline for this disease. To date, no new drug has qualified to be added to the current therapeutic arsenal comprising cholinesterase inhibitors and the NMDA receptor antagonist memantine. Drugs in the pipeline include symptomatic therapies that are neurotransmitter-based, but mostly disease-modifying therapies. The latter have yielded disappointing results by focusing mainly on the two pathophysiological hallmarks of Alzheimer's disease: Aβ amyloid deposits and tau protein aggregates forming neurofibrillary tangles. These unsuccessful trials may have resulted from studying these drugs 'too late' relative to Alzheimer's disease onset, in addition to focusing only on the amyloid cascade. In fact, Alzheimer's disease is a complex multifactorial disease. Combining different biomarkers might enhance our ability to identify those patients most at risk of developing the disease, and better predict their conversion rates. Furthermore, adopting an integrative treatment approach by targeting additional pathophysiological pathways in Alzheimer's disease such as inflammation and oxidative stress could be the key to better outcomes in Alzheimer's disease pharmacotherapy research. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink